<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02207868</url>
  </required_header>
  <id_info>
    <org_study_id>EVA 3D</org_study_id>
    <nct_id>NCT02207868</nct_id>
  </id_info>
  <brief_title>3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH</brief_title>
  <acronym>EVA3D</acronym>
  <official_title>3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH (EVA 3D Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Steringer-Mascherbauer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elisabethinen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to document the left and right ventricular function in patients with
      sclerodermia associated pulmonal arterial hypertension via 3D echocardiography. The results
      of this study should help to generate hypothesis for further future studies.

      The primary hypothesis is that the increased use of modern image guided methods could provide
      essential aspects for the follow up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 3D echocardiography could provide early and detailed information about the changes in the
      left and right ventricle.

      The prediction of sclerodermia associated pulmonary arterial hypertension (PAH) is rather
      adverse, so it makes sense to evaluate relevant changes of the left-ventricular longitudinal
      strain soon to adapt the PAH specific therapy accordingly.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the left ventricular longitudinal strain</measure>
    <time_frame>day 90 (+/- 7 days)</time_frame>
    <description>echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>wall thickness</measure>
    <time_frame>90 days (+/- 7 days)</time_frame>
    <description>echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular ejection fracture</measure>
    <time_frame>90 days (+/- 7 Days)</time_frame>
    <description>echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular stroke volume</measure>
    <time_frame>90 days (+/- 7 days)</time_frame>
    <description>echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tricuspid Annular Plane Systolic Excursion (TAPSE)</measure>
    <time_frame>90 days (+/- 7 days)</time_frame>
    <description>echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>right ventricular fractional area change</measure>
    <time_frame>90 (+/- 7 days)</time_frame>
    <description>echocardiography</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with pulmonary arterial hypertension associated with WHO group 1 who start with a
        parenteral prostanoidtherapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;17

          -  pulmonary arterial hypertension (PAH) associated with WHO group 1 who start a
             parenteral prostanoid-therapy

          -  written informed consent

          -  prostanoid naive

          -  no change of the PAH specific therapy within 3 weeks of the recruitment to the study

        Exclusion Criteria:

          -  pregnancy and lactation period

          -  Women of child bearing potential who do not use an effective and secure method for
             birth control

          -  severe chronic kidney insufficiency (glomerular filtration rate &lt;30), which will
             remain for more than 3 months

          -  liver-insufficiency Child C

          -  life expectancy shorter than the course of the study (for example because of malignant
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regina Steringer-Mascherbauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus der Elisabethinen Linz GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Regina Steringer-Mascherbauer, MD</last_name>
    <phone>0043/732/7676</phone>
    <phone_ext>4916</phone_ext>
    <email>regina.mascherbauer@elisabethinen.or.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Ploechl</last_name>
    <phone>0043/732/7676</phone>
    <phone_ext>4415</phone_ext>
    <email>andrea.ploechl@elisabethinen.or.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz GmbH</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Steringer-Mascherbauer, MD</last_name>
      <phone>0043/732/7676</phone>
      <phone_ext>4916</phone_ext>
      <email>regina.mascherbauer@elisabethinen.or.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2014</study_first_submitted>
  <study_first_submitted_qc>August 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2014</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Elisabethinen Hospital</investigator_affiliation>
    <investigator_full_name>Regina Steringer-Mascherbauer</investigator_full_name>
    <investigator_title>OA Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

